Vectibix 100 mg Infusion 5 ml

Vectibix 100 mg Infusion 5 ml belongs to a class of monoclonal antibodies. It is used alone or with other anticancer medicines to treat wild-type RAS metastatic colorectal cancer (mCRC). Metastatic colorectal cancer (mCRC) is a type of cancer of the colon or rectum that has spread to other areas of the body.

Vectibix 100 mg Infusion 5 ml contains Panitumumab, which works by slowing or stopping the growth of cancer cells. As a result, it prevents the cancer from spreading.

Vectibix 100 mg Infusion 5 ml will be administered under the supervision of a physician qualified by training and an experienced oncologist. The most frequent side effects of Vectibix 100 mg Infusion 5 ml when taken with other chemotherapy medications include diarrhea, paronychia (nail inflammation), fatigue, nausea, and diarrhea; stomatitis (oral mucosal inflammation and redness), mucosal inflammation, asthenia (abnormal physical weakness), anorexia, hypomagnesemia (an electrolyte disturbance), hypokalemia, rash, skin rash, itchiness, and dry skin. You should talk to your doctor if these side effects persist or worsen.

Notify your doctor of any food or medication allergies or hypersensitivity reactions before taking the Vectibix 100 mg Infusion 5 ml. Vectibix 100 mg Infusion 5 ml may cause fetal harm when administered to a pregnant woman. Before beginning treatment, discuss effective contraception with your healthcare professional. Inform them immediately if you or your partner become pregnant while undergoing therapy. Breastfeeding is not recommended while taking panitumumab. 

Vectibix 100 mg Infusion 5 ml contains Panitumumab, a monoclonal antibody. It is used alone or in conjunction with other anticancer medications to treat metastatic colorectal cancer (mCRC). It works by slowing or preventing the growth of cancer cells. As a result, it inhibits the cancer from spreading.

Before taking Vectibix 100 mg Infusion 5 ml, inform your doctor about your medical history and ongoing therapies to rule out potential adverse effects or interactions. The dosage of this medicine will be based on your health condition. Your doctor may adjust your dose during therapy based on the treatment results. Vectibix 100 mg Infusion 5 ml may cause infusion reactions, interstitial lung disease (ILD), ocular toxicity, and dermatologic or soft tissue toxicity. Hence, inform the doctor immediately if you suffer any side effects. If therapy needs to be stopped, your doctor will make that decision. Vectibix 100 mg Infusion 5 ml is recommended not to be used in pregnant women. Therefore, if you become pregnant while on treatment with Panitumumab, tell your doctor immediately. Breastfeeding is not recommended while taking panitumumab. Alcohol should be avoided during treatment with this medicine. Drive only if alert, as the Vectibix 100 mg Infusion 5 ml may cause nausea or tiredness.

• Keep all appointments with your doctor and the laboratory. Your doctor will order certain tests to check your body's response to Vectibix 100 mg Infusion 5 ml.
• Pregnancy testing is recommended prior to starting treatment with Vectibix 100 mg Infusion 5 ml.
• Do not donate sperm throughout treatment and at least two months after treatment.